BR112022003142A2 - Entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular - Google Patents

Entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular

Info

Publication number
BR112022003142A2
BR112022003142A2 BR112022003142A BR112022003142A BR112022003142A2 BR 112022003142 A2 BR112022003142 A2 BR 112022003142A2 BR 112022003142 A BR112022003142 A BR 112022003142A BR 112022003142 A BR112022003142 A BR 112022003142A BR 112022003142 A2 BR112022003142 A2 BR 112022003142A2
Authority
BR
Brazil
Prior art keywords
sarcoglycan
alpha
muscular dystrophy
adeno
associated virus
Prior art date
Application number
BR112022003142A
Other languages
English (en)
Inventor
Danielle Griffin
R Mendell Jerry
Louise Rodino-Klapac
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of BR112022003142A2 publication Critical patent/BR112022003142A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Abstract

entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular. são descritos neste documento métodos de tratamento de distrofia muscular em um sujeito, compreendendo a administração de um vetor de aav recombinante aavrh74.tmck.hscga usando uma via sistêmica de administração e a uma dose de cerca de 1,0 x 1012 vg/kg a cerca de 5,0 x 1015 vg/kg. são divulgados ainda métodos de expressão do gene alfa-sarcoglicano em uma célula ou em um sujeito em necessidade do mesmo, diminuindo um nível sérico de ck e aumentando as fibras positivas para alfa-sarcoglicano no tecido muscular de um sujeito.
BR112022003142A 2019-08-21 2020-08-21 Entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular BR112022003142A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962889749P 2019-08-21 2019-08-21
US202063014934P 2020-04-24 2020-04-24
US202063022843P 2020-05-11 2020-05-11
PCT/US2020/047339 WO2021035120A1 (en) 2019-08-21 2020-08-21 Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
BR112022003142A2 true BR112022003142A2 (pt) 2022-05-17

Family

ID=72340432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003142A BR112022003142A2 (pt) 2019-08-21 2020-08-21 Entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular

Country Status (15)

Country Link
US (1) US20220290180A1 (pt)
EP (1) EP4017871B1 (pt)
JP (1) JP2022544627A (pt)
KR (1) KR20220092489A (pt)
CN (1) CN114945583A (pt)
AU (1) AU2020331987A1 (pt)
BR (1) BR112022003142A2 (pt)
CA (1) CA3150964A1 (pt)
CO (1) CO2022002864A2 (pt)
DK (1) DK4017871T3 (pt)
FI (1) FI4017871T3 (pt)
IL (1) IL290734A (pt)
MX (1) MX2022002132A (pt)
TW (1) TW202120532A (pt)
WO (1) WO2021035120A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4198046A1 (en) 2021-12-16 2023-06-21 Genethon Alpha-sarcoglycan gene transfer increase using modified itr sequences

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
AU688428B2 (en) 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
KR20000068501A (ko) 1996-09-06 2000-11-25 트러스티스 오브 더 유니버시티 오브 펜실바니아 재조합 아데노-관련 바이러스 지정 유전자 요법을 위한 방법
EP1009808B1 (en) 1997-09-05 2012-12-05 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2001083692A2 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
WO2009137006A2 (en) * 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
CA3021057A1 (en) * 2016-04-15 2017-10-19 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy

Also Published As

Publication number Publication date
AU2020331987A1 (en) 2022-03-31
CA3150964A1 (en) 2021-02-25
JP2022544627A (ja) 2022-10-19
FI4017871T3 (fi) 2024-04-22
TW202120532A (zh) 2021-06-01
CN114945583A (zh) 2022-08-26
CO2022002864A2 (es) 2022-07-08
KR20220092489A (ko) 2022-07-01
MX2022002132A (es) 2022-05-18
WO2021035120A1 (en) 2021-02-25
DK4017871T3 (da) 2024-04-22
EP4017871A1 (en) 2022-06-29
US20220290180A1 (en) 2022-09-15
IL290734A (en) 2022-04-01
EP4017871B1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
BR112021021156A2 (pt) Terapêuticos anticorpos totalmente humanos pós-tradução modificados
WO2019079496A3 (en) Fully-human post-translationally modified antibody therapeutics
CY1126080T1 (el) Χορηγηση αδενο-σχετιζομενου ιικου διαβιβαστη μικρο-δυστροφινης με εξειδικευση στους μυς για τη θεραπευτικη αντιμετωπιση της μυïκης δυστροφιας
MX2022003857A (es) Vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el uso de los mismos en la distrofia muscular.
MY195438A (en) Adeno-Associated Virus Vector Delivery of Micro-Dystrophin to Treat Muscular Dystrophy
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
WO2015109391A1 (en) Smc combination therapy for the treatment of cancer
PH12020500239A1 (en) Factor viii (fviii) gene therapy methods
MX2019007873A (es) Terapia génica para tratar la enfermedad de wilson.
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
MX2021010356A (es) SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR112022003142A2 (pt) Entrega de vetor de vírus adenoassociado de alfa-sarcoglicano e tratamento de distrofia muscular
WO2021151043A3 (en) Methods and compositions for treating and preventing viral infection
MX2016012558A (es) Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo.
CO2023000156A2 (es) Administración de vectores de virus adenoasociado para distrofias musculares
MX2021014789A (es) Vectores aav con el promotor de la proteina cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las celulas de schwann como la enfermedad de charcot-marie-tooth.
AR121175A1 (es) ADMINISTRACIÓN DE VECTORES DE VIRUS ADENOASOCIADO DE a-SARCOGLICANO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR
BR112023003736A2 (pt) Distribuição sistêmica do vetor de vírus adeno-associado expressando g-sarcoglicana e o tratamento da distrofia muscular
MX2022004352A (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
BR112017022621A2 (pt) liberação do gene de smad7 como uma substância terapêutica
EA202192346A1 (ru) Доставка -саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии
MX2018011744A (es) Metodos y composiciones para el tratamiento de esclerosis lateral amiotrofica.
EA202090957A1 (ru) Терапевтические средства на основе полностью человеческих посттрансляционно модифицированных антител
WO2018136647A3 (en) Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels